Changes in VEGF and VEGFR immunohistochemical staining, together with decreases of the CD31-positive intratumoral vascular network, corroborate the powerful antiangiogenic and antiproliferative effect of sorafenib on thyroid tumor cells. This evidence concerns the gene KDR and thyroid tumor.